---
layout: post
title: "Pulmonary-Allergy Drugs Advisory Committee; Amendment of Notice"
date: 2026-02-05 19:01:11 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-22700
original_published: 2022-10-19 00:00:00 +0000
significance: 8.00
---

# Pulmonary-Allergy Drugs Advisory Committee; Amendment of Notice

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 19, 2022 00:00 UTC
**Document Number:** 2022-22700

## Summary

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Pulmonary-Allergy Drugs Advisory Committee. This meeting was announced in the Federal Register of September 8, 2022. The amendment is being made to reflect changes in the DATES, ADDRESSES, and SUPPLEMENTARY INFORMATION portions of the document. The meeting was rescheduled to allow time for FDA to review new information submitted to the application. There are no other changes.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/19/2022-22700/pulmonary-allergy-drugs-advisory-committee-amendment-of-notice)
- API: https://www.federalregister.gov/api/v1/documents/2022-22700

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
